Bromelain
Bromelain is an enzyme mixture from pineapple; human studies show benefits for swelling after operations and for wound debridement.
We evaluated 147 human studies on Bromelain, including 47 randomised controlled trials and 16 meta-analyses or systematic reviews; the controlled studies include 4,437 participants in total. As of 8 October 2026.
1. What Is Bromelain? Occurrence, Origin and Forms
Bromelain is a mixture of proteolytic enzymes found in the pineapple (Ananas comosus); preparations are mainly made from the stem of the plant. It is sold as a powder, tablet or capsule with a stated enzyme activity, and also as an ingredient of combination products. It is studied, among other things, in swelling after surgery, in osteoarthritis, in inflammation and in sinusitis.
The enzymes occur in the pineapple, in the fruit and in particularly high concentration in the stem of the plant. As a preparation, bromelain is taken orally and is also used in food processing.
For production, the pineapple stem is pressed, the enzyme is precipitated from the juice and purified; its activity is stated in standardised units rather than in milligrams. Studies mainly examine stem bromelain as a tablet or capsule, sometimes as a single substance and sometimes together with other enzymes or plant compounds.
Forms and Preparations Studied
- Stem bromelain from the pineapple stem
- Fruit bromelain from the fruit
- Powders, tablets and capsules with a stated enzyme activity
- Preparations with additional enzymes or plant compounds (combination products)
- Pineapple fruit and pineapple juice as food
Not covered on this page:
- Other plant proteases such as papain, ficin or actinidin from papaya, fig and kiwi
- Animal proteases such as trypsin and chymotrypsin, even when they occur in the same preparations
- The technical use of bromelain as an aid in food processing
2. What Does Bromelain Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Dental and maxillofacial surgery | mixed | moderate | 0 meta-analyses · 13 controlled · 1 other | 520 |
| Swelling and inflammation after surgery | mostly improved | moderate | 1 meta-analyses · 4 controlled · 15 other | 106 |
| Sinusitis | reviews only | low | 1 meta-analyses · 0 controlled · 2 other | 0 |
| Inflammation and inflammatory markers | mostly no difference | unclear | 1 meta-analyses · 2 controlled · 15 other | 60 |
| Osteoarthritis | observational data only | unclear | 0 meta-analyses · 0 controlled · 3 other | 0 |
| Other investigations | mostly improved | high | 8 meta-analyses · 8 controlled · 62 other | 382 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Bromelain, Dental and Maxillofacial Surgery: Human Studies
After wisdom tooth removal, bromelain reduced facial swelling compared with the procedure without bromelain 53 and relieved swelling and trismus more than aceclofenac 34. Purified bromelain and a bromelain-enriched pineapple extract each lowered ibuprofen need, pain and swelling after wisdom tooth removal more than placebo 42. After tooth removal with ridge preservation, pain and initially swelling were less under bromelain than under placebo 55. A mixture of baicalin, bromelain and escin relieved pain more than ibuprofen and placebo, but not swelling and trismus 32. After wisdom tooth, gum and root canal treatment, bromelain relieved pain similarly to aceclofenac, ibuprofen and diclofenac; the latter two acted faster at individual early time points 344652. A mouth rinse with bromelain did not remove more plaque than placebo 41; after gum surgery, the gums bled less often, and plaque and gum index did not differ 44. The studies were mostly small, some not randomized, and used different preparations, often without stating the enzyme activity.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 24 Ajami et al. 2025 | randomised controlled · 135 participants | Bromelain 200 mg (ANAHEAL) or Bromelain 150 mg plus turmeric 300 mg (ANAHEAL PLUS); one tablet immediately after separator placement; 48 hours of observation; vs. Ibuprofen 400 mg and bromelain alone | pain (VAS) 2 h after separator placement: improved (p = 0.006); pain (VAS) 6 h after separator placement: improved (p = 0.025); chewing function pain at 48 h: worsened (p = 0.024) |
| 34 Gupta et al. 2022 | randomised controlled · 72 participants | Bromelain (source and enzyme activity not specified); 7 postoperative days; vs. Aceclofenac (group A) | severity of edema: improved (P < 0.001); trismus: improved (P < 0.001); pain (analgesic efficacy): no difference (P > 0.05) |
| 37 Abbasi et al. 2025 | randomised controlled · 60 participants | Anahil capsule (bromelain) plus acetaminophen; 500 mg Anahil capsule and 500 mg acetaminophen every 6 h; until pain relief, maximum 2 days; vs. placebo plus 500 mg acetaminophen every 6 h | Postendodontic pain (VAS) at 6 and 12 h: no difference (P = 0.875) |
| 41 Rose et al. 2020 | randomised controlled · 43 participants | Bromelain enzyme pre-rinse vs. powdered-sugar placebo; two crossover visits; vs. Placebo pre-rinse; additionally tooth brushing and Waterpik | plaque scores post-rinse: no difference (P = .190); plaque scores post-brushing: no difference (P = .764); plaque scores post-Waterpik: no difference (P = .882) |
| 42 Colletti et al. 2024 | randomised controlled · 42 participants | Brome-Inf® (pineapple extract with titrated bromelain) or purified bromelain; started day of surgery, continued 7 days; vs. placebo, three arms | ibuprofen (NSAID) requirement days 1–7: improved (p < 0.0001); pain reduction: improved (p < 0.0001); swelling reduction: improved (p < 0.0001) |
| 43 Aggarwal et al. 2026 | randomised controlled · 30 participants | Bromelain gel versus Carie-Care gel for chemomechanical caries removal; vs. Carie-Care gel | Time taken for caries removal: unclear (statistically significant); Effectiveness of caries removal, pain perception and behavior: no difference (no statistically significant differences) |
| 44 Babazade et al. 2023 | randomised controlled · 28 participants | Anaheal (bromelain) 500 mg capsules; 500 mg twice daily before meals, 1 g/day; one week; assessment four weeks after treatment end; vs. placebo, similar shape and color, same pharmaceutical company | bleeding on probing (BOP): improved (0% vs. 35.7%, P = 0.014); gingival index (GI): no difference (P = 0.120); plaque index (PI): no difference (17.71 ± 2.12 vs. 18.28 ± 2.49, P = 0.520) |
| 45 Bhupal et al. 2025 | randomised controlled · 24 participants | Bromelain paste as intracanal medicament (stem or fruit bromelain not specified); not reported; 7 days; vs. Triple antibiotic paste and 2% chlorhexidine gel | Reduction in CFU/mL of Enterococcus faecalis: improved (3.11 × 10^5 ± 0.26 CFU/mL) |
Further studies in this area: 46 52 53 54 55 124
Bromelain, Swelling and Inflammation After Surgery: Human Studies
After operations, bromelain reduced swelling and bruises: after rhinoplasty, bruises and eye hemorrhages were less on the seventh day than with placebo, swelling was not 49. Bromelain capsules with a stated enzyme activity reduced edema more than placebo after eyelid surgery, bruises only on the third day 39. The evidence is moderate, as only a few controlled trials tested bromelain alone. Several studies tested mixtures, such as bromelain with trypsin and rutoside 2126 or with diosmin, melilotus and hesperidin 48; their results cannot be attributed to bromelain alone. It remains open what role the stated enzyme activity, the origin from stem or fruit and the respective preparation play in the extent of the benefit.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Manouchehri et al. 2026 | systematic review · 696 participants | Bromelain, form and enzyme activity not reported; not reported; up to at least postoperative day 7; vs. control/placebo, details not reported | Postoperative ecchymosis: improved (reduced ecchymosis by postoperative day 7) |
| 8 Avadanei-Luca et al. 2026 | systematic review · 9 participants | Bromelain-based enzymatic debridement (NexoBrid, anacaulase-bcdb); vs. Control groups in preclinical studies (necrosis zones, re-epithelialization) | Selective eschar removal with dermal preservation: unclear; Full-thickness necrosis of zone of stasis: unclear (67% partial- vs. 100% full-thickness necrosis; p = 0.05); Viable dermal thickness: unclear (1.1 ± 0.7 mm) |
| 36 Rahimi-Movaghar et al. 2026 | randomised controlled · 60 participants | Bromelain 1500 mg/day, Rataheal™, oral supplementation; 1500 mg/day; 15 days postoperatively; vs. standard care alone | time to suture removal: improved (2.6 days, 95% CI: 0.74-4.11; p = 0.006); early wound healing score (day 7): improved (7.2 vs. 5, p < 0.001); early wound healing score (day 14): improved (8.56 vs. 7.3, p = 0.014) |
| 39 Shamloo et al. 2026 | randomised controlled · 46 participants | bromelain capsules 200 mg (500 GDU), stem or fruit not specified; every 8 hours; 2 weeks, assessed on days 1, 3, 7, 11; vs. identical placebo capsules containing starch | edema score (photographic scale 1-4) on day 3: improved (p<0.001); edema score on day 7: improved (p=0.0002); edema score on day 11: improved (p=0.001) |
| 49 Rahmaty et al. 2025 | randomised controlled | Bromelain (form and enzyme activity not stated in abstract); Assessment up to postoperative day 7; vs. Placebo, double-blind | Ecchymosis of both eyes, day 7: improved (p = 0.012); Subconjunctival haemorrhage, day 7: improved (p = 0.015); Periorbital oedema: no difference |
| 55 Chisci et al. 2022 | controlled | Oral bromelain from pineapple stem; 40 mg; 14 days (t1=2, t2=7, t3=14 days); vs. Placebo | Postoperative swelling: improved (r = -0.79, p = 0.0034); Postoperative swelling: improved (r = -0.81, p = 0.0020); Postoperative swelling: no difference (r = -0.34, p = 0.2967) |
| 56 Marchica et al. 2026 | cohort study · 2,238 participants | NexoBrid® (bromelain-based enzymatic debridement); vs. standard surgical treatment (excision) | Need for escharotomy: improved (OR 0.47, p < 0.001); Skin grafting: worsened; Number of surgical procedures: worsened |
| 57 Bulla et al. 2025 | cohort study · 300 participants | Nexobrid® (bromelain-based enzymatic debridement); Treatment 2015–2020; vs. Comparison with traditional clinical assessment | Improved burn depth diagnosis: improved; Avoidance of unnecessary surgeries: improved; Blood loss: worsened |
Further studies in this area: 67 69 72 73 76 79 86 97 104 106 123 124
Bromelain and Sinusitis: Human Studies
For bromelain alone in sinusitis, only review articles are available. According to a systematic review, bromelain could be effective in sinusitis 14. Another review describes a randomized study in children with acute sinusitis in which the children recovered faster with bromelain alone than with standard therapy with or without bromelain 7. In chronic sinusitis, a combination preparation of black currant, Boswellia serrata, bromelain and vitamin D in addition to the corticosteroid spray improved mucosal redness and runny nose more than the spray alone 68. The evidence is overall low; dedicated controlled trials with bromelain alone are still pending.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 7 Karkos et al. 2007 | systematic review · 116 participants | Bromelain (pineapple enzyme), source/activity not stated; vs. bromelain monotherapy vs bromelain plus standard therapy vs standard therapy alone | faster recovery: improved |
| 14 Leelakanok et al. 2023 | systematic review | Oral and topical bromelain preparations (form/origin unclear); vs. Controls (placebo/other treatment) | Effectiveness against sinusitis: improved |
| 68 De et al. 2023 | case-control study · 60 participants | Oral supplement with Ribes nigrum, Boswellia serrata, Bromelain, Vitamin D; 1 dose daily for 30 days or 2 doses daily for 15 days; 15 or 30 days; vs. Nasal steroid only (control) | nasal mucosal hyperemia and rhinorrhea: improved (statistically significant differences from the control) |
Bromelain, Inflammation and Inflammatory Markers: Human Studies
After traumatic brain injury, bromelain in a randomized trial lowered IL-6 more than placebo, while CRP, MDA and antioxidant capacity did not differ 47. In the same study, severity scores and mortality after two months were lower with bromelain 47. In hospitalized COVID-19 patients, a mixture of quercetin, vitamin C and bromelain lowered CRP and ferritin more than routine care, but did not reduce clinical events over the course 17. A randomized controlled trial with an oral enzyme combination of bromelain, trypsin and rutoside in knee osteoarthritis found higher levels of α2-macroglobulin and interleukin-10 40. The evidence is low; most controlled trials tested mixtures, studies with bromelain alone are still pending.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Sudarman et al. 2026 | meta-analysis · 596 participants | Topical bromelain mixture (enzymatic debridement); vs. Standard care | Infection rate: no difference |
| 13 Pereira et al. 2023 | systematic review | Bromelain alone or combined with other oral compounds; isolated 200–1050 mg/day; combined 99.9–1200 mg/day; 1 to 16 weeks; vs. randomized controlled trials (control not specified) | Inflammatory parameters (IL-12, PGE-2, COX-2, IL-6, IL-8, TNF-α, IL-1β, IL-10, CRP etc.): unclear |
| 36 Rahimi-Movaghar et al. 2026 | randomised controlled · 60 participants | Bromelain 1500 mg/day, Rataheal™, oral supplementation; 1500 mg/day; 15 days postoperatively; vs. standard care alone | inflammation: no difference |
| 47 Gheflati et al. 2026 | randomised controlled | oral bromelain, 600 mg daily via gavage; 600 mg daily; 14 days; vs. placebo, double-blind | IL-6 levels: improved (p < 0.001); CRP: no difference (p = 0.377); MDA: no difference (p = 0.061) |
| 58 Deplazes et al. 2024 | cohort study · 269 participants | Topical bromelain from pineapple stems; vs. Bromelain treatment vs. no bromelain treatment | First bacteremia: unclear (61 patients (23%)) |
| 60 Martines et al. 2024 | study · 224 participants | bromelain supplement (form and enzyme activity not stated); not stated; 15 days and 60 days of therapy; vs. no control group described | mucus secretion: improved (reduced mucus secretions); OME symptoms: improved (notable improvements) |
| 66 Drago et al. 2024 | cohort study · 62 participants | Dietary supplement with baicalin, bromelain and escin; 90 days (T0, T1 at 30 days, T2 at 90 days); vs. users vs. non-users (retrospective) | vessels' induration reduced: improved (53.3%); reduction of inflammatory signs: improved (33.3%); decrease in malleolar circumference: improved (29.0 (26.5-30.0) to 27.5 (26.0-28.5)) |
| 69 Hofmaenner et al. 2021 | case series · 59 participants | Bromelain-based enzymatic debridement; not reported; single session, follow-up 3 days; vs. regular use <15% TBSA vs. off-label >15% TBSA | leukocyte counts, CRP, PCT, lactate: no difference (No differences in leukocyte counts, CRP, PCT and lactate prior to application and during the following three days were observed) |
Further studies in this area: 82 88 93 100 101 108 109 116 122 123
Bromelain and Osteoarthritis: Human Studies
A systematic review of systemic enzyme therapy with trypsin, bromelain and rutoside trihydrate, partly together with diclofenac, reports less pain, better mouth opening, fewer joint sounds and easier eating and chewing in temporomandibular joint osteoarthritis 12. In knee osteoarthritis, an enzyme combination of bromelain, trypsin and rutoside improved pain and symptom scores compared with placebo, but not the overall score 40. Both results concern mixtures and cannot be attributed to bromelain alone. A study of a mixture of Boswellia serrata and bromelain found better quality of life, but had no comparison group 70. The evidence is overall low; controlled trials with bromelain alone in osteoarthritis are still pending.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 12 Shekhar et al. 2024 | systematic review | Systemic enzyme therapy: trypsin, bromelain, rutoside trihydrate; vs. Enzymes plus diclofenac versus NSAIDs alone | pain reduction: improved; mouth opening: improved; joint noise: improved |
| 70 Italiano et al. 2020 | case series · 49 participants | Gastroresistant food supplement containing Boswellia serrata and bromelain; 1 to 6 months (follow-up 3.0 ± 0.7 months); vs. No control group, baseline versus follow-up comparison | Quality of life (total score): improved; Quality of life (7 of 10 individual questions): improved |
| 71 Desideri et al. 2022 | study · 46 participants | OPERA® capsule with alpha-lipoic acid, Boswellia serrata, methylsulfonylmethane, bromelain; one hard-gelatin capsule daily; 6 months (T0 to T3); vs. no comparator arm; before-after comparison | symptom resolution by CTCAE: improved (10 out of 46 patients); symptom resolution by VAS: improved (5 patients); arthralgia-related pain by PRAI: improved (p = 0.0001) |
Bromelain: Further Outcomes in Studies
In deep burns and chronic wounds, a bromelain-based enzyme preparation for topical application cleaned the wound faster and more often completely in meta-analyses and randomized trials 3614152933. Burns healed more often without excision or skin graft 345; however, the time to wound closure in burns and chronic wounds did not differ from the comparison treatment 3433. In venous leg ulcers, the bromelain preparation cleaned the wound faster and more often completely than a collagenase ointment, and granulation was also more often complete 51. A bromelain-enriched pineapple extract relieved pain and swelling in children with orchitis and epididymitis more than placebo, in addition to antibiotics in both groups 38. After Mohs surgery with flap reconstruction, wounds healed faster with oral bromelain than with standard care, with no confirmed difference in pain 36. The later scar quality did not differ from standard surgical treatment in meta-analyses and a randomized pediatric study 34550. A combination preparation of essential oils, bromelain and green propolis led to clinical healing more often than placebo in acute bronchitis 18. The robustness is high for enzymatic debridement; the study on venous leg ulcers was funded by the manufacturer 29.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Gremmler et al. 2021 | systematic review · 3,008 participants | Proteolytic enzymes (bromelain, papain, chymotrypsin), mainly oral; vs. Enzyme therapy plus conventional cancer therapy vs. conventional therapy | Tolerability of anticancer therapy; Anticancer effects and survival rates: unclear; Side-effects of enzyme therapy |
| 3 Sudarman et al. 2026 | meta-analysis · 596 participants | Topical bromelain mixture (enzymatic debridement); vs. Standard care | Time to complete debridement: improved (MD -3.92; p < 0.00001); Rate of spontaneous healing: improved (MD 71.00; p < 0.00001); Surgical excision rate: improved (OR 0.08 (p < 0.0002)) |
| 4 De et al. 2025 | systematic review · 484 participants | Bromelain-based enzymatic debridement (e.g. Nexobrid); vs. Standard of care (surgical debridement) | Time to eschar removal: improved (MD -7.60 days 95% CI [-9.76, -5.44]; I2 = 70%); Risk of surgical excision: improved (RR 0.17; 95% CI [0.06, 0.47]; I2 = 79%); Need for autografts: improved (RR 0.40; 95% CI [0.18, 0.93]; I2 = 76%) |
| 5 Sacasa et al. 2026 | meta-analysis · 336 participants | Bromelain-based enzymatic debridement (BBD); vs. Standard of care (SOC) | Proportion requiring surgical excision: improved (RR, 0.11; 95% CI, 0.06-0.23; I² = 0%); Autograft use: improved; Time to debridement: improved |
| 6 Günay et al. 2026 | systematic review · 314 participants | Topical bromelain-based enzymatic debridement (BBD); vs. Standard care or vehicle | Complete debridement: improved (RR 2.81, 95% CI 1.15-6.86); Adverse events (RR 1.02, 95% CI 0.76-1.36) |
| 8 Avadanei-Luca et al. 2026 | systematic review · 9 participants | Bromelain-based enzymatic debridement (NexoBrid, anacaulase-bcdb); vs. Control groups in preclinical studies (necrosis zones, re-epithelialization) | Human histological findings (dermal homogenisation, vascular congestion, pseudoeschar): unclear |
| 9 Mohammed et al. 2025 | systematic review | Bromelain supplementation, source and enzyme activity not reported | Glycemic control (blood glucose, glycemic indices): improved; Lipid profile: improved; AMPK stimulation in muscle cells (mechanism): unclear |
| 10 Buso et al. 2025 | systematic review | Bromelain with liposomal vitamin C, only in combination products; vs. no control; no studies on bromelain/vitamin C alone | Chronic venous disease symptoms: improved; Edema: improved |
Further studies in this area: 11 14 15 16 29 33 35 36 38 47 50 51 56 58 59 60 61 62 63 64 65 66 69 74 75 77 78 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 102 103 104 105 106 107 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 125
4. How Is Bromelain Dosed? Preparation, Dose and Duration in Studies
For oral use, bromelain was mostly given as a capsule, sometimes with stated enzyme activity 3944; on wounds, a bromelain-based enzyme product was used for wound cleaning 2933. In addition, a bromelain-enriched, freeze-dried pineapple extract was tested 3842. Several investigations tested mixtures, such as bromelain with trypsin and rutoside 212640, with baicalin and escin 32, or with quercetin and vitamin C 17; their results cannot be attributed to bromelain alone.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| QCB supplement: quercetin, vitamin C, bromelain (form/source/enzyme activity not stated) | — | from study baseline to discharge, intubation, or death | 17 |
| Atusin® CAP: essential oils, bromelain, green Brazilian propolis | — | 10 days | 18 |
| Bromelain-containing supplements (stem bromelain, enzyme activity not stated) | not reported | 14-day recovery period, perioperative intake | 19 |
| Oral mixture of fruit bromelain (190 mg), papain (95 mg), and ficin (95 mg) | 1, 2, or 3 capsules daily (low, middle, high) | 3 months | 20 |
| Tibrolin®: trypsin 48 mg, bromelain 90 mg, rutoside 100 mg tablet | 2 tablets orally three times daily for 7 days postoperatively | 7 days | 21 |
| Tibrolin® D: trypsin 48 mg, bromelain 90 mg, rutoside 100 mg, diclofenac 50 mg | 1 tablet three times daily | 7 days postoperatively | 22 |
| Shengji ointment combined with bromelain (form/activity not stated) | not stated, dressing change once daily | 4 weeks | 23 |
| Bromelain 200 mg (ANAHEAL) or Bromelain 150 mg plus turmeric 300 mg (ANAHEAL PLUS) | one tablet immediately after separator placement | 48 hours of observation | 24 |
| intravitreal aflibercept plus oral Lenidase (baicalin, bromelain, escin) | — | 24 months | 25 |
| Trypsin 100 mg/bromelain 90 mg/rutoside 48 mg (TBR); stem or fruit source not stated, enzyme activity not stated | Trypsin 100 mg/bromelain 90 mg/rutoside 48 mg once preoperatively | Single dose 1 h before block; follow-up up to 7 days | 26 |
| Flogostop Duo, oral, containing bromelain and Boswellia serrata among others | — | 20 days (TG1) or 30 days (TG2) | 27 |
| Bromelain-based enzymatic debridement (BBD) | — | daily up to 2 weeks, then 12 weeks follow-up | 28 |
| EX-02, Bromelain-based enzymatic debridement agent, topical, enzymatic activity not reported | daily topical application, up to 8 treatments within 2 weeks | up to 8 days treatment, follow-up up to 14 weeks | 29 |
| Wobenzym: bromelain 540-1080 mg/day plus rutoside and trypsin | bromelain 540-1080 mg/day, rutoside 600-1200 mg/day, trypsin 288-576 mg/day | 1 week before and 2 weeks after the race | 30 |
| EnMax tablets; comparator: trypsin-bromelain-rutoside enzyme formulation | not reported | 7 days | 31 |
5. Is Bromelain Safe? Side Effects in Studies
The studies report predominantly good tolerability; mentioned were mainly flatulence, nausea and headache 14. For use on wounds, a meta-analysis names burning, pain, fever and sepsis, but their relation to the product is uncertain; serious health risks were not reported 14. In controlled studies and a meta-analysis, adverse events under bromelain did not occur more frequently than in the comparison groups 62939.
| Study | Reported side effects |
|---|---|
| 1 Gremmler et al. 2021 | Mostly well tolerated; mainly gastrointestinal complaints such as diarrhea or meteorism |
| 2 Manouchehri et al. 2026 | adverse events rare and mild |
| 3 Sudarman et al. 2026 | No significant differences in infection rates or transfusion needs |
| 6 Günay et al. 2026 | Comparable adverse events (RR 1.02, 95% CI 0.76-1.36) |
| 10 Buso et al. 2025 | no major safety issues reported |
| 11 Pereira et al. 2025 | Mucosal dryness, arthralgia and peripheral neuropathy were reduced |
| 13 Pereira et al. 2023 | 11 participants with side effects, mainly gastrointestinal, two discontinued |
| 14 Leelakanok et al. 2023 | Flatulence, nausea, headache; topical: burning, pain, fever, sepsis |
| 15 Shoham et al. 2023 | Coagulopathy and burn wound infection investigated, no strong evidence |
| 16 Fusini et al. 2016 | interactions with drugs/supplements not evaluated |
| 18 Petkova et al. 2025 | No differences in adverse event incidence |
| 19 Harris et al. 2020 | not reported |
6. What Remains Open: Limits of the Evidence
- Many studies investigated combination products with other enzymes or plant substances, so the contribution of bromelain alone remains unclear.
- The stated enzyme activity, the origin from stem or fruit and the preparation form were often not reported.
- For osteoarthritis, controlled studies with bromelain alone are still pending, and for sinusitis, larger replications of the only pediatric study so far 7.
- Several studies were small, some not randomized or manufacturer-funded.
- Long-term data on tolerability and interactions with medications are still pending.
7. Bottom Line: What Is Established About Bromelain
Bromelain is a mixture of proteolytic enzymes from pineapple that is offered as a powder, tablet or capsule with stated enzyme activity. Bromelain is best studied for swelling after operations as well as a bromelain-based enzyme product for wound cleaning in burns and chronic wounds. Here, controlled studies and meta-analyses showed less swelling and bruising as well as fewer surgical interventions.
In dentistry, bromelain improved swelling and mouth opening; against pain, it worked better than placebo and similarly to common painkillers. For inflammatory markers, osteoarthritis and sinusitis, the results rest mainly on combination products or reviews, so the contribution of bromelain alone remains open. Tolerability is predominantly described as good, with gastrointestinal complaints as the most common side effects.
Frequently Asked Questions
How well has Bromelain been studied in humans?
We evaluated 147 human studies on Bromelain, including 47 randomised controlled trials and 16 meta-analyses or systematic reviews; the controlled studies include 4,437 participants in total. As of 8 October 2026.
Does Bromelain help with dental and maxillofacial surgery? What the studies show
Does Bromelain help with swelling and inflammation after surgery? What the studies show
Does Bromelain help with sinusitis? What the studies show
Does Bromelain help with inflammation and inflammatory markers? What the studies show
What is bromelain and in what form is it studied?
Bromelain is a mixture of proteolytic enzymes from pineapple, mainly from the stem of the plant. In studies, it is used as a powder, tablet or capsule with stated enzyme activity, sometimes also as a topical preparation for wound debridement. Individual studies tested a bromelain-enriched pineapple extract 3842.
For which complaints do human studies show benefits?
The strongest evidence concerns swelling and inflammation after operations as well as enzymatic debridement in burns and chronic wounds. Controlled studies found less swelling 3955 and bruising 3949 after operations, and meta-analyses found fewer surgical wound excisions in burns 45. In dental and maxillofacial surgery, benefits were shown for swelling and mouth opening 3453.
How do the results differ for pain?
For pain, the result depends on the comparison. Compared with placebo, bromelain relieved pain after dental procedures 4255; compared with aceclofenac, ibuprofen and diclofenac, it worked similarly, with the latter two acting faster at individual early time points 344652. A meta-analysis found a small but significant pain relief for oral bromelain compared with controls 14; after Mohs surgery, only a non-significant trend was shown for pain 36.
What should be considered with combination products?
Many studies investigated bromelain in mixtures, such as with trypsin and rutoside, with baicalin and escin, or with quercetin and vitamin C. Results of such combination products cannot be attributed to bromelain alone. For bromelain alone, controlled studies are still pending for several areas of use.
How tolerable is bromelain in the studies?
Sources
- 1Gremmler L, Kutschan S, Dörfler J, Büntzel J, Büntzel J, Hübner J · 2021
- 2Manouchehri K, Datta S, Levin M · 2026
- 3Sudarman JP, Sayudo IF, Park JY, Fernandes A, Machinski E, Aulia MHU et al. · 2026
- 4De Freitas LR, Udoma-Udofa OC, Reginato PH, Mitsui HC, Provinciatto H, Torres FC · 2025
- 5Sacasa F, Herdocia Baus G, Quach MP, George RE, Bentz ML, Poore SO et al. · 2026
- 6
- 7Karkos PD, Leong SC, Arya AK, Papouliakos SM, Apostolidou MT, Issing WJ · 2007
- 8Avadanei-Luca S, Moraru DC, Bulgaru-Iliescu AI, Tatar R, Nacea I, Amarandei AH et al. · 2026
- 9Mohammed JS, Ahmed AT, Singh M, Hanumanthayya M, Kazmi SW, Chahar M et al. · 2025
- 10Buso G, Santini P, Ghirardini F, Cannavacciuolo F, Visonà A, Zalunardo B et al. · 2025
- 11Supplementation Containing Bromelain on the Side Effects of Oncological Treatment: Systematic ReviewPereira IC, Passos RB, Viana CMC, Mascarenhas IF, Nascimento GTM, Silva FCCD et al. · 2025
- 12Shekhar A, Maddheshiya N, Adit, Rastogi V, Ramalingam K · 2024
- 13Pereira IC, Sátiro Vieira EE, de Oliveira Torres LR, Carneiro da Silva FC, de Castro E Sousa JM, Torres-Leal FL · 2023
- 14Leelakanok N, Petchsomrit A, Janurai T, Saechan C, Sunsandee N · 2023
- 15Shoham Y, Gasteratos K, Singer AJ, Krieger Y, Silberstein E, Goverman J · 2023
- 16Fusini F, Bisicchia S, Bottegoni C, Gigante A, Zanchini F, Busilacchi A · 2016
- 17Önal H, Arslan B, Üçüncü Ergun N, Topuz Ş, Yilmaz Semerci S, Kurnaz ME et al. · 2021
- 18Petkova D, Petkov R, Hodzhev V, Ivanov Y, Hadjiev V · 2025
- 19Harris L, Darby P · 2020
- 20Ma JW, Hung JL, Takeuchi M, Shieh PC, Horng CT · 2022
- 21Dewan B, Shinde S, Motwani N · 2025
- 22
- 23Sun X, Jing J, Dai R, Zhu C, Sun Y, Sun J et al. · 2024
- 24Ajami S, Hosseini SH, Babanouri N, Hashemi Z · 2025
- 25Marolo P, Volti GL, Nicolosi A, Avitabile T, Longo A, Fallico M et al. · 2025
- 26
- 27Della Volpe A, De Luca P, De Lucia A, Martines F, Piroli P, D'Ascanio L et al. · 2022
- 28Carter MJ, Snyder RJ, Zarbiv KD, Katz-Levy Y, Haviv A, Klinger E et al. · 2026
- 29Shoham Y, Snyder RJ, Katz Levy Y, David Zarbiv K, Klinger E, Kramer M et al. · 2024
- 30Schoenfeld J, Grabs V, Nieman DC, Holdenrieder S, Haller B, Halle M et al. · 2026
- 31Suryawanshi A, Patkar H, Aute S, Rathi PC, Rathi CL, Risbud SP et al. · 2025
- 32Isola G, Matarese M, Ramaglia L, Iorio-Siciliano V, Cordasco G, Matarese G · 2019
- 33Shoham Y, Shapira E, Haik J, Harats M, Egozi D, Robinson D et al. · 2021
- 34
- 35Delgarm P, Mokhtare M, Ebrahimi Daryani N, Abolghasemi J, Rahideh ST · 2025
- 36Rahimi-Movaghar E, Ehtemami A, Ghaneiyan M, Tahouri T, Hedayati Omami S, Fahimi H · 2026
- 37Abbasi F, Abbasi B, Rezazadeh M, Ghazalgoo A · 2025
- 38Colletti A, Sangiorgio L, Martelli A, Pellizzato M, Cravotto G · 2025
- 39Shamloo M, Rafiei M, Esmaeili A, Zamani Barsari F, Golparvaran S, Aalizade A et al. · 2026
- 40Henrotin Y, Pap T, Lieten S, Badot V, Dubuc JE, Urbin-Choffray D et al. · 2025
- 41Rose J, Ghoneima A, Lippert F, Maxwell L, Eckert G, Stewart KT · 2020
- 42Colletti A, Procchio C, Pisano M, Martelli A, Pellizzato M, Cravotto G · 2024
- 43Aggarwal N, Rathore AS, Mathur R, Goyal AK, Tiwari S, Deshmukh AV · 2026
- 44Babazade H, Mirzaagha A, Konarizadeh S · 2023
- 45Bhupal SD, Patel SP, Gulve MN, Kolhe SJ, Kolhe PS, Pawar PA · 2025
- 46Faramarzi M, Sadighi M, Shirmohamadi A, Kazemi R, Zohdi M · 2023
- 47Gheflati A, Rashid Mayvan M, Ardestani MM, Mirghazanfari SM, Hazrati E, Kalantar MS et al. · 2026
- 48Montanaro F, Pettenuzzo G, Malandra S, Veccia A, Porcaro AB, Gozzo A et al. · 2026
- 49Rahmaty B, Naraghi M, Mesbahi A, Mohebbi A, Sadeghi B, Zadeh AR et al. · 2025
- 50Shoham Y, Rosenberg L, Narayan RP, Staubach R, Bene R, Kakola M et al. · 2025
- 51Dove CR, Snyder RJ, Zarbiv KD, Levy YK, Haviv A, Klinger E et al. · 2025
- 52
- 53The role of oral bromelain on "bad outcome" in mandibular third molar surgery. A split-mouth comparative studyParrini S, De Ambrosi C, Chisci G · 2023
- 54Nikhade P, Agrawal P, Mahapatra J, Suryawanshi T, Bhopatkar J, Umate L · 2023
- 55Chisci G, Fredianelli L · 2022
- 56Marchica P, Ranno R, D'Alessio R, Di Lonardo A, Giudice G, Merelli S et al. · 2026
- 57Bulla A, Rivas Nicolls DA, Lopez Martinez JA, Aguirrezabala JA, Visiedo MB, Baena J et al. · 2025
- 58Deplazes BC, Hofmaenner DA, Scheier TC, Epprecht J, Mayer M, Schweizer TA et al. · 2024
- 59Schiano di Visconte M, Sarnari S, Guttadauro A, Chiarelli M, Favetta U · 2026
- 60Martines F, Malta G, Cannizzaro E, Kelly T, Salvago P, Plescia F · 2024
- 61Pfister P, Garcia Wendel PD, Kim BS, Schuepbach RA, Steiger P, Camen G et al. · 2023
- 62
- 63Laurens Acevedo M, Usua GM, Barret JP · 2025
- 64
- 65Corrales-Benítez C, González-Peinado D, González-Miranda Á, Martínez-Méndez JR · 2022
- 66Drago SFA, Rottura M, Molonia A, Gianguzzo VM, Pallio G, Irrera N et al. · 2024
- 67Grünherz L, Michienzi R, Schaller C, Rittirsch D, Uyulmaz S, Kim BS et al. · 2023
- 68De Luca P, D'Ascanio L, Cingolani C, Latini G, Grigaliute E, Di Mauro P et al. · 2023
- 69Hofmaenner DA, Steiger P, Schuepbach RA, Klinzing S, Waldner M, Klein H et al. · 2021
- 70Italiano G, Raimondo M, Giannetti G, Gargiulo A · 2020
- 71Desideri I, Lucidi S, Francolini G, Meattini I, Ciccone LP, Salvestrini V et al. · 2022
- 72ECONOMIC ANALYSIS OF ENZYMATIC DEBRIDEMENT VERSUS STANDARD BURN CARE: A RETROSPECTIVE ANALYSISMinic J, Vestita M, Vigato E, Dallapozza E, Shoham Y, Lavagnolo U et al. · 2024
- 73Landi F, Tosato M, Terranova R, Rubini G, Mammarella F, Cacciatore S et al. · 2025
- 74Vingolo EM, Calabro M, Mascolo S, Miccichè F, Casillo L, Lupo S et al. · 2025
- 75A Retrospective Review of an Off-label Bromelain-based Selective Enzymatic Debridement (Nexobrid®) in the Treatment of Deep, Partial, and Full Thickness Burns and Hard to Heal WoundsHarats M, Haik J, Cleary M, Vashurin I, Aviv U, Kornhaber R · 2020
- 76Buta MR, Annand D, Findeisen S, Hickey SA, Sheridan RL, Friedstat JS et al. · 2023
- 77Lombardo GAG, Ciancio F, Violini H, Sapuppo C, Zagami S, Vena A et al. · 2024
- 78555 Pain Management During Bromelain-Based Enzymatic Debridement in a U.S. Adult Burn Center· 2023
- 79Bowers C, Randawa A, Sloan B, Anwar U, Phipps A, Muthayya P · 2022
- 80299 Donor Site Reduction with Combined Use of Bromelain Enzymatic Debridement and Autologous Skin Cell Suspension· 2023
- 81Capitelli-McMahon H, McCrossan S, Kershaw J, Muthayya P, Anwar MU, Carter A et al. · 2024
- 82Ke K, Pillai K, Mekkawy AH, Akhter J, Badar S, Valle SJ et al. · 2021
- 83Desideri I, Francolini G, Becherini C, Terziani F, Delli Paoli C, Olmetto E et al. · 2017
- 84Kamel A, Abdelseed H, Albalawi Y, Aslsalameen E, Almutairi Y, Alkattan A · 2020
- 85D'Andrea M, Dell'Aquila C, Barbano L, Menna F, Renzo AD, Colacino G et al. · 2026
- 86Arkoulis N, Mabvuure NT, Smith A, Barnes DE · 2021
- 87Korzeniowski T, Strużyna J, Torres K · 2022
- 88771 Enzymatic Burn Wound Debridement: The Learning Curve· 2023
- 89Serror K, Tasigiorgos S, Levi J, Oren N, Boccara D, Vassiliu P et al. · 2026
- 90Schmidt SV, Drysch M, Hinzmann J, Reinkemeier F, Puscz F, Füth M et al. · 2026
- 91"Minimally Invasive" Skin Grafting With Enzymatic Debridement and Autologous Skin Cell Spray: A Retrospective Case SeriesKahn SA, Raghava N, Gaweda G, Hink A, Holmes Iv J, Hickerson W et al. · 2023
- 92
- 93Snyder RJ, Singer AJ, Dove CR, Heisler S, Petusevsky H, James G et al. · 2023
- 94Korzeniowski T, Grywalska E, Strużyna J, Bugaj-Tobiasz M, Surowiecka A, Korona-Głowniak I et al. · 2022
- 95793 "Minimally Invasive" Skin Grafting with Enzymatic Debridement and Autologous Skin Cell SuspensionKahn S, Gaweda G, Halicki E, Hirsch J, Hink A, Hickerson W et al. · 2022
- 96Altpeter S, Wach MM, Giran E, Derby J, Beasley S, Pingpank JF et al. · 2026
- 97622 Oral Ketamine Administration During Bromelain Based Enzymatic Debridement of Burn InjuryHalicki E, Kahn S, Condeni M, Hirsch J, Turner J · 2022
- 98CONSENSUS ON THE APPLICATION AND CARE OF BROMELAIN-BASED ENZYMATIC DEBRIDEMENT ON BURNSGonzalez L, Gonzalez R, Callejas I, Roig G, Seoane N, Minguez S et al. · 2024
- 99Minic J, Vigato E, Shoham Y, Lavagnolo U, Governa M · 2024
- 100601 Bromelain Based Enzymatic Debridement Followed by Application of Autologous Cell Suspension for Treatment of BurnsWilliams A, Mbaka M, Ledbetter K, Huett W, Simmons J, Bright A · 2022
- 101Gund MP, Lehnertz L, Hannig M, Dudek J, Pütz N, Rupf S · 2026
- 102
- 103Lam AR, Bazzi K, Valle SJ, Morris DL · 2021
- 104Hinzmann J, Schmidt SV, Macedo Santos E, Fueth M, Drysch M, Steubing Y et al. · 2026
- 105
- 106Ferancikova N, Bukovcan P, Sarkozyova N, Dragunova J, Cucorova V, Koller J · 2020
- 107Yadav P, Stigall K, Johnson HE, Rayapati AO, Chopra N · 2016
- 108Pati A, Das BK, Pattanaik SS, Panda AK · 2026
- 109Hewgley WP, Black J, Jansen JO, Hurst S, White E, Fairburn SC et al. · 2026
- 110Ardeshiri H, Ghorbani M, Nazarinia MA, Falamarzi K, Tamaddon AM, Azarpira N · 2025
- 111Sun SL, Sarofim M, Morris DL · 2024
- 112Serracanta J, Baena J, Martinez-Mendez JR, Sanchez-Sanchez M, Sanchez-Sanchez M, Lopez-Suso E et al. · 2023
- 113Yang J, Glenn D, Lodh S, Valle S, Morris DL · 2023
- 114Skalkos E, Chen KL, Wijayawardana R, Morris DL · 2023
- 115D'Aloisio R, Di Antonio L, Toto L, Rispoli M, Di Iorio A, Delvecchio G et al. · 2022
- 116Sethia Y, Polak-Szczybyło E, Tabarkiewicz J · 2025
- 117Sanduzzi Zamparelli S, Sanduzzi Zamparelli A, Bocchino M · 2025
- 118Locci C, Chicconi E, Antonucci R · 2024
- 119Mathioudaki E, Vitsos A, Rallis MC · 2024
- 120Bordeanu-Diaconescu EM, Grama S, Grosu-Bularda A, Frunza A, Andrei MC, Neagu TP et al. · 2024
- 121Bromelain and acetylcysteine (BromAc®): a novel approach to the treatment of mucinous tumoursWen HK, Valle SJ, Morris DL · 2023
- 122Hikisz P, Bernasinska-Slomczewska J · 2021
- 123Varilla C, Marcone M, Paiva L, Baptista J · 2021
- 124Knackstedt R, Gatherwright J · 2020
- 125Heaton LE, Davis JK, Rawson ES, Nuccio RP, Witard OC, Stein KW et al. · 2017
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.